{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:48:43Z","timestamp":1770061723119,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.molmet.2024.102016","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:29:49Z","timestamp":1724452189000},"page":"102016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-792X","authenticated-orcid":false,"given":"Pavel","family":"Burda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alzbeta","family":"Hlavackova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vendula","family":"Polivkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Curik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Laznicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Krizkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Suttnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina Machova","family":"Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.molmet.2024.102016_bib1","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.molmet.2024.102016_bib2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.molmet.2024.102016_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","article-title":"Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment","volume":"9","author":"Kekale","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.molmet.2024.102016_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.molmet.2024.102016_bib5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.molmet.2024.102016_bib6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.molmet.2024.102016_bib7","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.molmet.2024.102016_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.molmet.2024.102016_bib9","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.molmet.2024.102016_bib10","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.molmet.2024.102016_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","article-title":"A\u00a0general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation","volume":"33","author":"Houten","year":"2010","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5\u20136","key":"10.1016\/j.molmet.2024.102016_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.mam.2004.06.006","article-title":"Carnitine: a nutritional, biosynthetic, and functional perspective","volume":"25","author":"Steiber","year":"2004","journal-title":"Mol Aspect Med"},{"issue":"2","key":"10.1016\/j.molmet.2024.102016_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.30087","article-title":"Disorders of carnitine transport and the carnitine cycle","volume":"142C","author":"Longo","year":"2006","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.1016\/j.molmet.2024.102016_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/humu.21607","article-title":"Genotype-phenotype correlation in primary carnitine deficiency","volume":"33","author":"Rose","year":"2012","journal-title":"Hum Mutat"},{"issue":"7","key":"10.1016\/j.molmet.2024.102016_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.molmet.2024.102016_bib16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1053\/j.ajkd.2008.05.031","article-title":"Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis","volume":"52","author":"Lynch","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.molmet.2024.102016_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cgh.2014.12.005","article-title":"L-Carnitine reduces muscle cramps in patients with cirrhosis","volume":"13","author":"Nakanishi","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.molmet.2024.102016_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.molmet.2024.102016_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.744373","article-title":"Somatic mutations in oncogenes are in chronic myeloid leukemia acquired de novo via deregulated base-excision repair and alternative non-homologous end joining","volume":"11","author":"Curik","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.molmet.2024.102016_bib20","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.cgh.2015.02.033","article-title":"Muscle cramps in cirrhosis: a moving target","volume":"13","author":"Mehta","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.molmet.2024.102016_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/138920011796504536","article-title":"L-carnitine--metabolic functions and meaning in humans life","volume":"12","author":"Pekala","year":"2011","journal-title":"Curr Drug Metabol"},{"issue":"8","key":"10.1016\/j.molmet.2024.102016_bib22","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/s41375-019-0443-7","article-title":"Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"33","author":"Janssen","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.molmet.2024.102016_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1359-6446(02)02179-7","article-title":"Metabolic profiling of cell growth and death in cancer: applications in drug discovery","volume":"7","author":"Boros","year":"2002","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.molmet.2024.102016_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00129785-200505050-00002","article-title":"Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications","volume":"5","author":"Serkova","year":"2005","journal-title":"Am J PharmacoGenomics"},{"issue":"19","key":"10.1016\/j.molmet.2024.102016_bib25","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.molmet.2024.102016_bib26","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Kominsky","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.molmet.2024.102016_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133134","article-title":"Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells","volume":"20","author":"De Rosa","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.molmet.2024.102016_bib28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3389\/fphar.2020.01106","article-title":"Imatinib and dasatinib provoke mitochondrial dysfunction leading to oxidative stress in C2C12 myotubes and human RD cells","volume":"11","author":"Bouitbir","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.molmet.2024.102016_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2018.07.001","article-title":"Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes","volume":"155","author":"Damaraju","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.molmet.2024.102016_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-019-00860-x","article-title":"Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor","volume":"38","author":"Chae","year":"2020","journal-title":"Invest N Drugs"},{"issue":"7","key":"10.1016\/j.molmet.2024.102016_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271307","article-title":"The effect of levocarnitine supplementation on dialysis-related hypotension: a systematic review, meta-analysis, and trial sequential analysis","volume":"17","author":"Chewcharat","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.molmet.2024.102016_bib32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824001479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824001479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T09:19:09Z","timestamp":1726391949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877824001479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"alternative-id":["S2212877824001479"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2024.102016","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2024.102016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102016"}}